<td class= Dadun
   (New user)
Help  | Contact  |  Castellano English  

Dadun > Depósito Académico > CIFA (Centro de Investigación en Farmacobiología Aplicada) > Unidad de I+D de Medicamentos > DA - CIFA - I+D de medicamentos - Artículos de revistas >

Quinoxaline 1,4-di-N-oxide and the Potential for Treating Tuberculosis
Authors: Vicente, E. (Esther)
Villar, R. (Raquel)
Perez-Silanes, S. (Silvia)
Aldana, I. (Ignacio)
Goldman, R.C. (Robert C.)
Monge, A. (Antonio)
Solano, B. (Beatriz)
Burguete, A. (Asunción)
Ancizu, S. (Saioa)
Zarranz, B. (Belén)
Jaso, A. (Andrés)
Marin, A. (Adoración)
Keywords: Tuberculosis
Quinoxaline 1,4-di-N-oxide
Issue Date: 2011
Publisher: Bentham Science Publishers
Publisher version:
ISSN: 1871-5265
Citation: Vicente E, Villar R, Perez-Silanes S, Aldana I, Goldman RC, Monge A. Quinoxaline 1,4-di-N-oxide and the potential for treating tuberculosis. Infect Disord Drug Targets 2011 Apr 1;11(2):196-204.
New drugs active against drug-resistant tuberculosis are urgently needed to extend the range of TB treatment options to cover drug resistant infections. Quinoxaline derivatives show very interesting biological properties (antibacterial, antiviral, anticancer, antifungal, antihelmintic, insecticidal) and evaluation of their medicinal chemistry is still in progress. In this review we report the properties and the recent developments of quinoxaline 1,4-di-N-oxide derivatives as potential anti-tuberculosis agents. Specific agents are reviewed that have excellent antitubercular drug properties, are active on drug resistant strains and non-replicating mycobacteria. The properties of select analogs that have in vivo activity in the low dose aerosol infection model in mice will be reviewed.
Permanent link:
Appears in Collections:DA - Farmacia - Orgánica - Artículos de revista
DA - CIFA - I+D de medicamentos - Artículos de revistas

Files in This Item:
File:  Infectious Diseases - Drug Targets, 11, 196-204.pdf
Size:  244,42 kB
Format:  Adobe PDF
 View / Open 

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.